Sugi Predict

Sugi Predict / Targets / BRAF

BRAF

Serine/threonine-protein kinase B-raf · P15056 · BRAF on Sugi Atlas →

263,882 patent compounds predicted against BRAF, 160,358 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL84259 SCHEMBL84259 0.69 20/20
SCHEMBL69214 SCHEMBL69214 0.67 20/20
SCHEMBL69215 SCHEMBL69215 0.67 20/20
SCHEMBL84262 SCHEMBL84262 0.66 20/20
SCHEMBL69547 SCHEMBL69547 0.64 20/20
SCHEMBL69548 SCHEMBL69548 0.64 20/20
SCHEMBL68328 SCHEMBL68328 0.64 20/20
SCHEMBL68091 SCHEMBL68091 0.64 20/20
SCHEMBL68092 SCHEMBL68092 0.64 20/20
SCHEMBL68835 SCHEMBL68835 0.64 20/20
SCHEMBL68836 SCHEMBL68836 0.64 20/20
SCHEMBL67330 SCHEMBL67330 0.63 20/20
SCHEMBL67331 SCHEMBL67331 0.63 20/20
SCHEMBL91501 SCHEMBL91501 0.63 20/20
SCHEMBL91575 SCHEMBL91575 0.63 20/20
SCHEMBL68275 SCHEMBL68275 0.63 20/20
SCHEMBL68276 SCHEMBL68276 0.63 20/20
SCHEMBL67068 SCHEMBL67068 0.63 20/20
SCHEMBL67069 SCHEMBL67069 0.63 20/20
SCHEMBL68428 SCHEMBL68428 0.63 20/20

Clinical trials — most relevant to BRAF by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. PHASE2/PHASE3NOT_YET_RECRUITING
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer PHASE2COMPLETED
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations PHASE1/PHASE2COMPLETED
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer PHASE1/PHASE2COMPLETED
MCS110 With BRAF/MEK Inhibition in Patients With Melanoma PHASE1/PHASE2COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations PHASE2ACTIVE_NOT_RECRUITING
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma PHASE2COMPLETED
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma PHASE2COMPLETED
Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma PHASE2ACTIVE_NOT_RECRUITING
Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations PHASE2ACTIVE_NOT_RECRUITING
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma PHASE2ACTIVE_NOT_RECRUITING
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma PHASE2COMPLETED
LUT017 Gel for Venous Leg Ulcers and Chronic Non-Healing Skin Wounds in Adults PHASE1NOT_YET_RECRUITING
A Study of ASN007 in Patients With Advanced Solid Tumors PHASE1COMPLETED
Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors PHASE1COMPLETED
Study of LUT017 Gel to Improve Healing of Skin Wounds After Removal of Benign Lesions in Healthy Adults PHASE1NOT_YET_RECRUITING
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma PHASE1ACTIVE_NOT_RECRUITING
HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors PHASE1UNKNOWN
Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma PHASE1WITHDRAWN
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation nanCOMPLETED
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment nanACTIVE_NOT_RECRUITING
Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma nanNO_LONGER_AVAILABLE
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Immune Monitoring in Metastatic Melanoma nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a BRAF binder may also engage these)

ProteinNameSimilarity
Q04982 — 1.000 Q04982 →
P34908 — 1.000 P34908 →
P28028 — 1.000 P28028 →
P04627 — 0.991 P04627 →
ARAF Serine/threonine-protein kinase A-Raf 0.991 landscape →
RAF1 RAF proto-oncogene serine/threonine-protein kinase 0.989 landscape →
Q99N57 — 0.989 Q99N57 →
A7E3S4 — 0.989 A7E3S4 →
Q9ESL4 — 0.989 Q9ESL4 →
P09560 — 0.988 P09560 →
P05625 — 0.987 P05625 →
O19004 — 0.987 O19004 →
P14056 — 0.986 P14056 →
Q62136 — 0.986 Q62136 →
Q5R5M7 — 0.985 Q5R5M7 →
P27966 — 0.984 P27966 →
MAP3K20 Mitogen-activated protein kinase kinase kinase 20 0.984 landscape →
P11345 — 0.984 P11345 →
Q99JP0 — 0.983 Q99JP0 →
A7MBL8 — 0.983 A7MBL8 →
MAP4K3 Mitogen-activated protein kinase kinase kinase kinase 3 0.983 landscape →
Q8N556 — 0.982 Q8N556 →
MAP3K7 Mitogen-activated protein kinase kinase kinase 7 0.981 landscape →
Q62925 — 0.981 Q62925 →
A0JNJ1 — 0.981 A0JNJ1 →
Q6F6B3 — 0.980 Q6F6B3 →
Q96NE9 — 0.980 Q96NE9 →
P53666 — 0.980 P53666 →
BCR Breakpoint cluster region protein 0.980 landscape →
Q92625 — 0.980 Q92625 →